Lifecore Biomedical (LFCR) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street futures dip after AI rout, telecoms slide
- Brent crude hits more than five-month high on concern over Middle East escalation
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts LFCR Hot Sheet
Join SI Premium – FREE
Lifecore Biomedical (NASDAQ: LFCR) reported Q2 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $36.44 million versus the consensus estimate of $35.36 million.
For earnings history and earnings-related data on Lifecore Biomedical (LFCR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
- HawkEye 360 launches Cluster 16 satellite trio on Rocket Lab rocket
- Needham Starts Diodes (DIOD) at Buy, 'Significant Margin Upside'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
